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Sanzo: Patenting Biotherapeutics

PATENTING BIOTHERAPEUTICS
Michael A. Sanzo*

I.

INTRODUCTION

During the previous decade, the development of methods for
producing proteins by recombinant DNA techniques has led to a tremendous growth in the biotechnology industry.! There is widespread
optimism that the powerful biological tools now available will lead to
the development of a host of new drugs for combating disease in
humans.2 Four recombinant products are presently on the market:
insulin, growth hormone, alpha-interferon, and tissue plasminogen
activator (hereinafter "tPA").3 Other drugs are under development and
will become available in the near future.4 These therapeutic drugs
have a number of features in common: all are proteins normally
found in the human body; all perform the same functions as therapeutics that they perform naturally; all are presently being manufactured
using recombinant DNA methods; and all have been the subject of
extensive litigation.' For the purposes of this Article, the group of

* LD. St. Louis University School of Law, 1992; Ph.D. Albany Medical College,
1981. The author is an associate with the firm of Sterne, Kessler, Goldstein & Fox,
Washington, D.C. The views expressed are solely those of the author.
1. See OFFICE OF TECHNOLOGY ASSESSMENT, CONGRESS OF THE UNITED STATES, NEW

DEVELOPMENTS IN BIOTECHNOLOGY 55-190 (1988); see also Emily A. Arakaki, A Study of
the U.S. Competitive Position in Biotechnology, in HIGH TECHNOLOGY INDUSTRIES: PROFILES
AND OUTLOOK: BIOTECHNOLOGY 39 (1984).
2. See THE INTERNATIONAL BIOTECHNOLOGY HANDBOOK 177-94 (1988).
3. See Marcia Barinaga, Problems with Anti-Clotting Drug, 335 NATURE 751 (1988)
(discussing tissue plasminogen activator); see also Rudy M. Baum, Biotech Industry Moving
Pharmaceutical Products to Market, CHEMICAL & ENGINEERING NEWS, July 20, 1987, at 11
(discussing human growth hormones, human insulin, alpha-interferon, and hepatitis B vaccine);
Joan O'C. Hamilton, Biotech's First Superstar, Bus. WK., April 14, 1986, at 68 (discussing
the use of human growth hormones); Interferon Approved for Marketing by FDA, CHEmICAL
& ENGINEERING NEWS, June 9, 1986, at 7 (discussing alpha-interferon).
4. See OFFICE OF TECHNOLOGY ASSESSMENT, supra note 1, at 161-90; see also THE
INTERNATIONAL BIOTECHNOLOGY HANDBOOK, supra note 2.
5. E.g., Amgen, Inc. v. Chugai Pharmaceutical Co., 706 F. Supp. 94 (D. Mass. 1989)
(erythropoietin); Hoffman-LaRoche, Inc. v. Burroughs Wellcome Co., 10 U.S.P.Q. 2d (BNA)
1602 (D. Md. 1989) (interferon); Genentech, Inc. v. Bowen, 676 F. Supp. 301 (D.D.C. 1987)
(growth hormone); Scripps Clinic & Research Found. v. Genentech, Inc., 666 F. Supp. 1379

Published by Scholarly Commons at Hofstra Law, 1991

1

Hofstra Law Review, Vol. 20, Iss. 2 [1991], Art. 4
HOFSTRA LAW REVIEW

[Vol. 20:387

drugs with these characteristics will be called "biotherapeutics."
This Article begins with a consideration of the general requirements of patentability under the Patent Act of 19526 (hereinafter the
"Act") and then addresses three issues that have been of particular
importance with regard to the patenting of biological inventions.7
The first issue raised by biotherapeutics is whether or not these
drugs constitute patentable subject matter under section 101 of the
Act.8 The characterization of biological inventions as "products of
nature" creates confusion between this issue and that of whether or
not a particular product is "novel" and "nonobvious," as required by
sections 102 and 103 of the Act, respectively.9
The second issue raised concerns the determination of
inventorship.' ° Biological inventions typically result from contributions by many independent researchers, and the criteria for determining who is entitled to patent a particular invention are lacking. It is
generally argued that the objective of promoting innovation is best
served by adopting a policy of ascribing inventorship to the first party
to determine the amino acid sequence of a protein, and by defining
the invention in terms of this sequence.
Finally, I address how the "doctrine of equivalents,"'" as a -test
12
for patent infringement, should be applied to biological inventions.
The test for infringement under this doctrine is based upon the similarity of molecules with regard to their function. This can lead to

(N.D. Cal. 1987) (Factor VIII:C). See Jane M. Marciniszyn, What has Happened Since'
Chakrabarty, 2 J. L. & HEALTH 141 (1988) (discussing biotechnology and patentability).
6. 35 U.S.C. §§ 1-376 (1988).
7. For purposes of this Article, biotherapeutics fall within the statutory definition of

what constitutes a drug.
8.

35 U.S.C. § 101 (1988).

9. Id. §§ 102-03. For examples of cases in which there was an intermingling of the
provisions of the patent statute, see In re Fisher, 307 F.2d 948 (C.C.P.A. 1962); Kuehmsted
v. Farbenfabriken of Elberfeld Co., 179 F. 701 (7th Cir. 1910); Parke-Davis & Co. v. H.K.
Mulford Co., 189 F. 95 (C.C.S.D.N.Y. 1911).
10. The terms "invention" and "inventor" are used in the sense described by Judge

Rich: "It is time to settle the point that the terms invent, inventor, inventive, and the like are
unrelated to deciding whether' the statutory requirements for patentability under the 1952 Act

have been met. There is always an invention; the issue is its patentability." In re Bergy, 596
F.2d 952, 962 (C.C.P.A. 1979). The term "inventorship" refers to the right of a particular

party to claim an invention as his. With certain exceptions, it is only this party who may
obtain a patent. 35 U.S.C. § 111 (1988).
11.

See infra notes 80-94 and accompanying text.

12. See Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605 (1950) (holding that the four flux claims of plaintiff's patent were infringed by defendant's device under

the doctrine of equivalents).

http://scholarlycommons.law.hofstra.edu/hlr/vol20/iss2/4

2

Sanzo: Patenting Biotherapeutics
PATENTING BIOTHERAPEUTICS

1991]

anomalous results when biological inventions are also def'med in
terms of their function.
In discussing the above topics, one particular product, tPA, is
often used as an example. 3 Tissue plasminogen activator is the most
profitable biotherapeutic presently on the market and has been the
source of extensive litigation throughout the past few years. 4
II.

GENERAL REQUIREMENTS OF PATENTABILITY:
NOVELTY AND UTILITY

In order to be patentable, an invention 5 must meet the requirements set forth by the Patent Act of 1952.16 Section 101 of the Act
defines patentable subject matter as "any new and useful process,
machine, manufacture, or composition of matter or any new and
useful improvement thereof.' 17 An invention that falls into one of
these categories must then meet the requirements of novelty, utility,
and nonobviousness, as set forth in other provisions of the Act. 8
Although each of these separate elements must be met for an invention to be patentable, 9 they have not been equally problematic in

13. Tissue plasminogen activator [hereinafter "tPA"] is a protein used in the treatment of
patients experiencing myocardial infarctions. It acts by binding to and dissolving fibrin clots
obstructing the flow of blood to the heart. It is the most successful drug ever marketed in
terms of gross first-year sales. See Joseph Loscalzo and Eugene Braunwald, Tssue Plasminogen Activator, 319 NEW ENG. J. MED. 925 (1988) (discussing tPA's therapeutic properties);
Barinaga, supra note 3 (discussing tPA's performance as a drug product).
14. See Patents: tPA Variants are Equivalent to Genentech's Patented tPa, 39 PAT.
TRADEMARK & COPYRIGHT J. (BNA) 503 (1990) (discussing a jury's finding that variants of
a genetically engineered protein (tPA) infringe patents of Genentech, Inc., under the doctrine
of equivalents); Paul G. Cole, United Kingdom: Revocation of Genentech's British Parent for
T-PA is Sustained by Court of Appeal, 37 PAT. TRADEMARK & COPYRIGHT J. (BNA) 206
(1988) (discussing the revocation of Genentech's patent for tPA in the United Kingdom); see
also David Swinbanks, Problems Over TPA Patent for Genentech in Japan, 333 NATURE 587
(1988); Carol Ezzell, Initial Sales of Genentech's TPA Set New Records, 331 NATURE 202
(1988) (reporting that, during the first six weeks that tPA was available, it accumulated $58
million in sales); M. Mitchell Waldrop, Companies Vie Over New Heart Drug, 237 SCIENCE
120 (1987) (discussing Genetech's battle to maintain its patent for tPA in the United Kingdom).
15. See supra note 10 for a definition of "invention."
16. See generally 35 U.S.C. §§ 1-376 (1988) (setting forth the requirements to obtain a
patent).
17. Id. § 101.
18. Id. §§ 102, 103, 112.
19. See Diamond v. Diehr, 450 U.S. 175 (1981) (holding that the patent was not invalid
for lack of novelty); General Motors Corp. v. Toyota Motor Co., 667 F.2d 504 (6th Cir.
1981) (holding that the patent was not invalid for obviousness); American Seating Co. v. National Seating Co., 586 F.2d 611 (6th Cir. 1978) (holding that the patent was invalid because
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the context of biological inventions. Neither questions of novelty nor
questions of utility have been the usual subjects of dispute in patents
on biotherapeutics.
The requirement of novelty is fulfilled as long as there is no
single description in the prior art that contains all of the elements of
the invention.20 Even trivial differences between the invention and
the prior art will be sufficient to make the invention "novel."" Not
surprisingly, inventors have little trouble in meeting this standard.
Similarly, the utility requirement seldom presents a problem for
inventors. An invention is not required to be superior to other similar
inventions. It is sufficient that it has some beneficial use.' This idea
was expressed by Justice Story more than 150 years ago:
It is not necessary to establish, that the invention is of such general
utility, as to supersede all other inventions now in practice to accomplish the same purpose. It is sufficient, that it has no obnoxious
or mischievous tendency, that it may be applied to practical uses,
and that so far as it is applied, it is salutary.'
The cost of litigation alone makes it unlikely that a patent dispute
will arise over a product's inability to meet such minimal requirements.24 It is also unlikely that corporations will invest the capital
needed to develop a biotherapeutic without first obtaining substantial
evidence that it will be of considerable value as a product.'
it was obvious to one of ordinary skill); Bolkcom v. Carborundum Co., 523 F.2d 492 (6th
Cir. 1975) (holding, inter alia, that the patent was valid because it satisfied the requirements
of novelty, utility and nonobviousness).
20. See Kalman v. Kimberly-Clark Corp., 713 F.2d 760 (Fed. Cir. 1983) (holding that
the patent was valid and infringed, since appellant had not established that advantageous
results were not the attributes of the claimed invention); Leinoff v. Louis Milona & Sons
Inc., 556 F. Supp. 273 (S.D.N.Y. 1982) (holding, inter alia, that the patent was not invalid
for lack of novelty, since none of the prior art relied upon by the defendant recited each of
the elements of the patent in the identical fashion as set forth in the claims); Maclaren v. BI-W Group Inc., 401 F. Supp. 283 (S.D.N.Y. 1975) (holding that the patent was not invalid
for obviousness since no single item of the prior art revealed the complete combination).
21. See, e.g., Eibel Process Co. v. Minnesota & Ont. Paper Co., 261 U.S. 45 (1923)
(holding, Inter alia, that an increase of at least 20% in the daily output of paper product was
sufficiently weighty evidence to sustain the presumption of new and useful).
22. National Slug Rejecters, Inc. v. A.B.T. Mfg. Corp., 164 F.2d 333 (7th Cir. 1947);
see also In re Oberweger, 115 F.2d 826 (C.C.P.A. 1940) (holding that a small degree of
utility is sufficient to support a patent); Fuller v. Berger, 120 F. 274 (7th Cir. 1903) (holding
that an invention is not void for lack of utility because it was used for immoral purposes).
23. Bedford v. Hunt, 3 F. Cas. 37 (C.C.D. Mass. 1817) (No. 1217).
24. Burroughs Wellcome claimed to have spent more than $2.5 million in its lawsuit
with Genentech. Genentech, Inc. v. Wellcome Found. Ltd., 14 U.S.P.Q. 2d (BNA) 1363, 1373
(D. Del. 1990).
25. On average, it costs more than $125 million to develop a new drug and to obtain
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In contrast to novelty and utility, questions concerning
inventorship, nonobviousness, and whether or not an invention constitutes patentable subject matter occur repeatedly. These questions are
considered below.

Ill. Do BIOTHERAPEUTICS CONSTITUTE PATENTABLE SUBJECT
MATTER? BIOTHERAPEUTICS AS "PRODUCTS OF NATURE"

Determining what constitutes patentable subject matter under
section 101 of the Act has proven to be one of the most difficult and
controversial tasks in patent law.26 The problem is compounded by
the fact that courts often fail to draw a distinction between the question of what constitutes patentable subject matter and the question of
whether or not that subject matter meets the other requirements of
patentability. The problem is exemplified by Judge Rich's comments
concerning the Supreme Court's decision in Parker v. Flook:2
[W]e find in Flook an unfortunate and apparently unconscious,
though clear, commingling of distinct statutory provisions which are
conceptually unrelated, namely, those pertaining to the categories of
inventions in § 101 [of the Act] which may be patentable and to the
conditions for patentability demanded by the statute for inventions
within the statutory categories, particularly the nonobviousness condition of § 103 ....
Thus, the questions of whether a particular invention is
novel or usefid are questions wholly apart from whether the invention falls into a category of statutory subject matter.28

The commingling, by courts, of unrelated provisions of the patent statute is typically manifested by the denial of patents for biological inventions because they are "products of nature. '29 There is,

FDA approval for sale. Allen E. Cato, The Challenge of the Clinical Development of Drugs,
in CLINIcAL DRUG TRIMS AND TRIBULATIONS 1, 3-5 (Allen E. Cato ed., 1988).
26. In re Walter, 618 F.2d 758 (C.C.P.A. 1980). Judge Rich, writing for the court, was
of the opinion that the "determination of statutory subject matter under § 101 [of the Act] in
the field here involved has proved to be one of the most difficult and controversial issues in
patent law." Id at 764.
27. 437 U.S. 584 (1978).
28. In re Bergy, 596 F.2d 952, 959, 960-61 (C.C.P.A. 1979); see also In re Sarkar, 588
F.2d 1330 (C.C.P.A. 1978) (holding, inter alia, that questions of novelty and nonobviousness
are irrelevant considerations to section 101 determinations).
29. See, e.g., Diamond v. Chakrabarty, 447 U.S. 303 (1980) (holding that plaintiff's live,
human-made micro-organism was patentable because the new bacteria had different characteristics from any found in nature, and that the fact that it was alive was without legal signifi-
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in fact, nothing in the patent statute precluding the patenting of products of nature. To the extent that such statements have a statutory
basis, they are really contentions that inventions are unpatentable
either because they lack novelty or are obvious.3"
A.

"Product of Nature" as a Contention that an
Invention Lacks Novelty

With regard to novelty, a "product of nature" denial is a contention that, because the product occurs naturally, it is not "new," as is
required under section 101 of the Act. 31 Under this interpretation,
the word "new" means never having existed before. However, such an
interpretation has no justification. Congress explicitly stated that the
meaning of "new," as used in section 101, is defined by section 102
of the Act. "Section 101 sets forth the subject matter that can be
patented, 'subject to the conditions and requirements of this title.' The
conditions under which a patent may be obtained follow, and section
102 covers the conditions relating to novelty. '32 "[The] statute is
split into two sections, section 101 relating to the subject matter for
which patents may be obtained, and section 102 defining statutory
3
novelty.0
When restated as a question of novelty under section 102, courts
have had little difficulty finding that biological inventions are patentable. For example, in considering whether a prostaglandin that had
been purified from sheep prostate glands fulfilled the statutory requirement of novelty, the court in In re Bergstrom' held:
It seems to us that the answer to that question [whether or not the
purified prostaglandin was novel] is self-evident: by definition, pure
materials necessarily differ from less pure or impure materials and,

cance in determining patentability); see also Funk Bros. Seed Co. v. Kalo Inoculant Co., 333
U.S. 127 (1948) (finding that plaintiff had discovered only "some of the handiwork of
nature" and, as such, the discovery was not patentable). See generally General Electric Co. v.
De Forest Radio Co., 28 F.2d 641 (3rd Cir. 1928) (holding that "[i]f it is a natural
thing . . . [plaintiff] cannot have a patent for it because a patent cannot be awarded for a
discovery or for a product of nature . .

").

30. See Comment, The Patentability of Living Organisms Under 35 U.S.C. § 101: In re
Bergey, 91 HARV. L. REV. 1357, 1360 (1978) (arguing that courts that have considered the
patentability of products of nature have rejected the patent claim on statutory requirements
like novelty or obviousness).
31. Id. at 1358.
32. H.R. REP. No. 1923, 82d Cong., 2d Sess. 6 (1952).
33. 35 U.S.C. § 101 (1983) (revision notes).
34. 427 F.2d 1394 (C.C.P.A. 1970).
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if the latter are the only ones existing . . . the "pure" materials are

"new" with respect to them.35
B.

"Product of Nature" as a Contention that an
Invention Was Obvious

The second potentially valid contention that may be expressed as
a denial based on an invention being a "product of nature" is that the
invention was obvious.36 The analysis is greatly simplified once it is
recognized that what is at issue is not whether or not an invention
falls within the section 101 categories of patentable subject matter,
but, rather, whether or not it fulfills the requirement of
nonobviousness of section 103 of the Act. Under section 103,
[a] patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title
[even if the requirement of novelty is met], if the differences between the subject matter sought to be patented and the prior art are
such that the subject matter as a whole would have been obvious at
the time the invention was made to a person having ordinary skill
in the art to which said subject matter pertains. 37
Section 103 was first interpreted by the Supreme Court in Graham v. John Deere, Co. 38 The Court stated that "[a]n invention
which has been made, and which is new in the sense that the same
thing has not been made before, may still not be patentable if the
difference between the new thing and what was known before is not
considered sufficiently great to warrant a patent."39 With regard to
biotherapeutics, courts have found that sufficient differences exist
where the invention offers some clear therapeutic advantage over
previous forms of the product. For example, in considering the patentability of vitamin B-12, a natural product of the liver, a federal district court wrote:
Before [the inventors] made it available to the world, pure crystalline vitamin B-12, as described and claimed in the '794 patent, did
not exist ....

The new product had such advantages over the

35. Id. at 1401-02 (footnote omitted).
36. See Comment, supra note 30, at 1358.
37. 35 U.S.C. § 103 (1983).
38. 383 U.S. 1 (1966).
39. Id at 14 (quoting S. REP. No. 1979, 82d Cong., 2d Sess. 6 (1952); H.R. REP. No.
1923, 82d Cong., 2d Sess. 7 (1952)).
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earlier liver extracts that it not only replaced them, but became, and
remains to this day, the universal treatment for pernicious anemia.
The new product has completely eliminated the harmful side effects
of the old liver preparations.'

It is important to recognize that it was not merely the change in form
(i.e., the purification) that made the vitamin patentable, but, rather,
that the change led to a product with substantially improved proper-

ties.
IV.

DEFINING INVENTIONS BY STRUCTURE: THE PROBLEM OF
DETERMINING INVENTORSHIP

A.

Phases in the Development of Biotherapeutics

Given that biotherapeutics are patentable subject matter, what
basis should be used for determining inventorship? These products are
typically developed by many different research groups performing
similar kinds of experiments. 4 The problem, then, is determining

40. Merck & Co.
Merck & Co. v. Olin
nothing in the language
ent upon a 'product of

v. Chase Chem. Co., 273 F. Supp. 68, 83 (D.N.J. 1967); see also
Mathieson Chem. Corp., 253 F.2d 156 (4th Cir. 1958). "There is
of the [Patent] Act [of 1952] which precludes the issuance of a patnature' when it is a 'new and useful composition of matter.' IdL at

161.
41. There are a number of articles that summarize the development and therapeutic uses
of the most promising biotherapeutics. Included among these are the following: Jerome E.
Groopman et al., Hematopoietic Growth Factors, 321 NEW ENG. J. MED. 1449 (1989)
(discussing the important applications of hematopoietic growth factors); Charles H. Kirkpatrick,
Biological Response Modifiers-nterferons, Interleukins, and Transfer Factor, 62 ANNALS
ALLERGY 170 (1989) (reviewing the effects of certain cell-derived soluble factors on the
immune system); 0. Mehls & R.N. Fine, The Use of Recombinant Growth Hormone for
Treatment of Growth Failure in Uremia, 9 SEMINARS NEPHROLOGY 43 (1989) (providing a
perspective for the therapeutic use of human recombinant growth hormones); Glenn F. Pierce
et al., The Use of Purified Cloning Factor Concentrates in Hemophilia, 261 JAMA 3434
(1989) (discussing the effects of purified clotting factors on eliminating greater amounts of
infectious agents in hemophiliacs); Claudio Ponticelli & Stefano Casati, Correction of Anaemia with Recombinant Human Erythropoietin, 52 NEPHRON 201 (1989) (concluding that anaemia can be fully corrected by recombinant human erythropoietin); H. Thomas & K. Sikora,
Biological Approaches to Cancer Therapy, 17 3. INT'L MmD. RES. 191 (1989) (stating that
the potential permutations and applications of biological therapy for cancer are great); C.G.D.
Brook, Treatment of Growth Deficiency, 30 CLINICAL ENDOCRINOLOGY 197 (1988) (discussing
the causes of growth deficiency and the effect of biosynthetic growth hormones on the
deficiency); Robert Califf et al., Experience with the Use of tPA in the Treatment of Acute
Myocardial Infarction, 17 ANNALS EMERGENCY MED. 1176 (1988) (arguing that thrombolytic
therapy offers the potential to reduce substantially the mortality of patients with acute myocardial infarction when given medical attention in the early stages); Robert A. Figlin,
Blotherapy with Interferon-1988, 15 SEMINARS ONCOLOGY 3 (1988) (reviewing the effects of
interferon therapy on human malignancy treatments); Leopold Floh6, Superoxide Dismutase for
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which of many possible inventors should be entitled to claim that she
made the invention. The developmental process may be divided into
four distinct phases: initial observations, determination of structure,
large scale production, and clinical testing and commercial production.
Phase I: Initial Observations: Typically, suspicions concerning
the existence of a novel biological factor begin with observations
made on impure extracts prepared from tissues or cells. For example,
the first indication of the existence of tPA came in 1947 when Tage
Astrup observed that certain crude tissue extracts dissolved fibrin.42
Since the activity did not appear to be due to any of the factors that
were then known to have fibrinolytic activity, Astrup speculated that
there might be a unique factor causing the effect.43 At the time, it
was not clear that the observation had any therapeutic significance or
that a new factor existed. During the following years, Astrup and
other investigators continued to make observations on impure mixtures.' Although the results were not entirely consistent with one
another, taken together they presented strong evidence for the existence of a new fibrin-dissolving protein.
Phase II: Determination of Structure: Once there is evidence of
the existence of a new factor of potential therapeutic value, development may follow one of two different paths. In some instances, researchers purify the protein to homogeneity,4 s determine its full or

Therapeutic Use: Clinical Experience, Dead Ends and Hopes, 84 MOLECULAR & CELLULAR
BIOCHEMISTRY 123 (1988) (reviewing the achievements and drawbacks of superoxide
dismutase); Jordan Gutterman, Overview of Advances in the Use of Biological Proteins in
Human Cancer, 15 SEMINARS ONCOLOGY 2 (1988) (arguing that major advances in the use
of biologics should significantly contribute to improving the survival of cancer patients); Craig
M. Kessler et al., Acute Pulmonary Embolism Treated with Thrombolytic Agents: Current
Status of tPA and Future Implications for Emergency Medicine, 17 ANNALS EMERGENCY
ME. 1216 (1988) (concluding that innovative approaches to the use of thrombolytic agents
may maximize their effectiveness).
42. Tage Astrup & Per M. Permin, Fibrinolysis in the Animal Organism, 159 NATURE
681 (1947) (reporting that profibrinolysin can be transformed into fibrinolysin by an activator
found in animal tissue cells).
43. Id at 682; see also Tage Astrup, Fibrinolysis in the organism, 11 J. HEMATOLOGY
781 (1956) (providing an analytical review of the fibrinolytic process).
44. See Sten Mullertz, A Plasminogen Activator in Spontaneously Active Human Blood,
82 PROC. Soc'Y EXPERIENTAL BIOLOGY & MED. 291 (1952) (reviewing an experiment on
fibrinolytic activity); see also Astrup, supra note 43.
45. There is no absolute way of showing that a protein is pure. The best that can be
done is to show that separation methods fail to reveal any inhomogeneities in a preparation;
hence, the term -purification to homogeneity." See ABRAHAM WHITE ET AL, PRINCIPLES OF
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partial amino acid sequence, and use this information to clone the
corresponding gene.46 In other instances, researchers rely on the immunological or biological properties of a protein in order to clone its
gene directly. 7 The full amirio acid sequence of the protein may
then be deduced by sequencing nucleic acid.48
Sequence determination represents a central event in the development of a biotherapeutic. For the first time, a specific biological
function may be associated with a well defined biochemical structure.
The time period from the initial observations suggesting the existence
of a molecule to the time its structure is determined can be extensive.
For example, the sequence of tPA was not determined
until over
49
Astrp.
by
observation
initial
the
after
years
thirty
Phase III: Large Scale Production: During the first two phases
of development, the structure and function of a potential
biotherapeutic are determined. This information is sufficient to form
the basis of a patent. A separate question is whether or not the invention will be of any practical therapeutic value. In order to determine
this, sufficient quantities of the protein must be produced to evaluate
its clinical properties-first in animals and later in humans." The
importance of being able to scale up production should not be underestimated; it has been a major stumbling block in the development of
even the most promising of drugs."'

BIOCHEMISTRY 134-36 (5th ed. 1973).
46. See, e.g., Richard M. Lawn & Gordon A. Vehar, The Molecular Genetics of Hemophilia, SCL AM., Mar. 1986, at 48 (discussing factor VII).
47. See, e.g., J. Michael Bishop, Oncogenes, Sci. AM., Mar. 1982, at 81 (discussing the
study of oncogenes, which make up tumor viruses, and which are believed to cause cancerous growth in healthy cells); see also Henry A. Erlich et al., Immunological Detection and
Characterization of Products Translated from Cloned DNA Fragments, in 68 METHODS IN
ENZYMOLOGY 443 (Ray Wu ed., 1979) (discussing the use of cloned DNA to detect functions and immunological properties of proteins).
48. JAMES DARNELL ET AL, MOLECULAR CELL BIOLOGY 236-48 (1986).
49. P.B. Wallhn, Tissue Plasminogen Activator Induced Fibrinolysis: Historical Landmarks and Present Achievements, in 7 PROGRESS IN FIBRINOLYSIs 3-11 (John F. Davidson et
al. eds., 1985).
50. The FDA requirements that must be met for a new drug to be approved may be
found in 21 U.S.C. section 355. Regulations cover animal testing, 21 C.F.R. §§ 312.22(c),
312.23 & 312.1(a)(2) (1990), as well as three separate phases of clinical trials. 21 C.F.R. §
312.21(a)-(c) (1990). Upon completion of clinical trials, a drug sponsor may submit a new
drug application ("NDA") according to the procedures set forth in 21 C.F.R. section 314.50
(1990).
51. See, e.g., Sidney Pestka, The Purfication and Manufacture of Human Interferons,
Sd. AM., Aug. 1983, at 37-38 (discussing the fact that the shortage and high cost of inter-
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Phase IV: Clinical Testing and Commercial Production: If, based
upon research in animals, it appears that a drug is a promising candidate for commercialization, it will be evaluated in humans 2 and a
determination will be made as to whether or not it can be profitably
manufactured. Clinical evaluation is an expensive undertaking that
typically requires years to complete.5 3
An examination of the progression described above suggests that
inventorship will be determined by events that occur during either
Phase I or Phase II. Although patents may be awarded on inventions
made during either of these phases, it is likely that only Phase II
patents will be of any long-term value. Moreover, as discussed below,
there are logical and practical reasons for adopting a policy of determining inventorship based solely upon events occurring during Phase
II.
B. Phase I Patents
During the initial phase of development, observations are made
on cell or tissue extracts and on partially purified preparations. Although patents may potentially be awarded on such materials,' 4 there
are a number of reasons why such patents are likely to be of minimal
value. First, patents on impure preparations lack specificity. The biological activities observed in such preparations may be due to the
interaction of several proteins, or to factors that are not proteins at
all.y5 Uncertainties concerning the nature of factors are compounded
by uncertainties caused by the complex biological assays that are
typically used to make observations.5 6 Consequently, it is difficult to
show that an alleged infringer used the same factor as that described
feron, a protein released by cells exposed to a virus, which then enables other cells to resist
the virus, has limited cancer studies and studies of the protein's effectiveness against viruses).
52. See 21 C.F.R. § 312.21 (a)-(c) (1990).
53. The average time required to complete the clinical development of a new drug and
obtain FDA approval is approximately nine years. The average remaining patent life of a
drug after approval for sale is approximately seven years. See Cato, supra note 25, at 5-6.
54. See In re Bergstrom, 427 F.2d 1394 (C.C.P.A. 1970) (holding that the distinction
between "pure" materials and less pure or "impure" materials results in the potential patentability of either, or possibly both, materials); see also In re Williams, 171 F.2d 319
(C.C.P.A. 1948) (holding that, where a patent already exists for an impure compound, a
patent claim for a pure ingredient of this compound may fail for lack of invention, although
not for lack of novelty).
55. See Fedor Bachmann et al., Partial Purification and Properties of the Plasminogen
Activator from Pig Heart, 3 BIoCHEMIsTRY 1578 (1964) (illustrating the uncertainties created
by the use of impure preparations).
56. Id
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in a patent.
A second reason why Phase I patents are likely to be of limited
value is that the inventions themselves are at a competitive disadvantage. Although crude preparations have occasionally been used to treat
patients in the past,5 7 proteins made by recombinant methods and
then purified prior to clinical administration offer such substantial
technical and therapeutic advantages that it is unlikely that extracts
containing undefined factors will be used to an appreciable extent in
58
the future.
Finally, patents on partially purified tissue extracts could be
easily circumvented by competitors. Such patents would apply only to
the specific preparation described and not to the factor within the
preparation responsible for the observed activity.5 9 Thus, a new and
patentable invention could be obtained by simply altering the extraction or purification procedure.
C.

Phase II Patents

Under section 112 of the Act, an invention must be specifically
and accurately defined.'
In order to define specifically a
biotherapeutic, a researcher must carry out two closely related processes. First, she must develop a procedure for obtaining the biologically active protein (or its gene) in pure form and, second, she must
determine its amino acid sequence. 61 Whereas different proteins may

57. See Genentech v. Bowen, 676 F. Supp. 301 (D.D.C. 1987) (discussing supplementing a patient's natural hGH with hGH derived from the pituitary glands of human cadavers);
Merck & Co. v. Chase Chem. Co., 273 F. Supp. 68 (D.N.J. 1967) (discussing preparation of
vitamin B-12 from the livers of various organisms).
58. One major disadvantage associated with the use of cell or tissue extracts is that, if
the source material is of human origin, there is likely to be a severe limitation on the
amount of such material available. See, e.g., Lawn & Vehar, supra note 46; see also Pestka,
supra note 51. In contrast, cloned genes produce an essentially unlimited amount of source
material. Id.
Another major disadvantage is that tissue extracts may be contaminated with pathogens
that are harmful or deadly to the recipients of such extracts. This danger is eliminated when
the proteins are produced by recombinant means. See infra note 64 and accompanying text;
see also Genetic Engineering May Cut Risk of Blood Infection in Hemophiliacs, N.Y. TIMS,
Dec. 27, 1990, at A16 (reporting that many hemophiliacs became infected with the AIDS
virus after receiving a blood-clotting protein derived from tainted blood, but that such infection could be avoided by using a recombinant protein that is now being tested).
59. See Bergstrom, 427 F.2d 1394.
60. 35 U.S.C. § 112 (1983).
61. The purification procedure is analogous to a map describing how to get to a
specific place. The amino acid sequence is analogous to an address that exactly defines that
place and distinguishes it from all others.
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have similar biological functions, their amino acid sequences are
absolutely unique.62 Since it is not until a researcher determines this
sequence that a biotherapeutic has been unambiguously identified, it
follows logically that the first researcher to make such a determination should be entitled to inventorship.6 3
Determining inventorship based upon priority in defining the
amino acid sequence of a protein makes sense for other reasons as
well. Purification and sequence determination are key events in the
evaluation of the therapeutic potential of a protein. Until it has been
identified and is available in pure form, there is no way to determine
whether an observed therapeutic effect is due to a protein or to some
impurity present in the administered preparation.
Moreover, in light of recent experiences in which patients treated
with impure biological materials have developed AIDS or CreutzfeldtJakob disease, it is unlikely that crude drug preparations will be considered to be suitable for clinical use in the future.' The transformation of a biological compound from a state of therapeutic unsuitability
to a state at which therapeutic applications become feasible has traditionally provided grounds for patentability. 65 For example, in consid-

62. For example, tPA, pro-urokinase, and streptokinase all have similar functions, but
they differ greatly in structure. See H. Straub et al., Thrombolytic Effect of Streptokinase on
Coronary Artery Occlusion in Acute Myocardial Infarction by Conventional Intravenous
Administration Over 24 Hours, in 7 PROGRESS IN FIBRINOLYSIS 39-40 (John F. Davidson et
al., eds. 1985) (illustrating the functions and properties of streptokinase); see also D. Collen
& H.R. Lijnen, Thrombolysis with Human Tssue-Type Plasminogen Activator, in 7 PROGRESS
N FIBRiNOLYSiS, supra, at 66-70 (illustrating the functions and properties of IPA); V.
Gurewich et al., Fibrin-Specific Lysis of Pulmonary Enboli by Pro-Urokinase (Pro-UK) in
Rabbits and Dogs, in 7 PROGRESS IN FIBRINOLYSIS, supra, at 59-62 (illustrating the functions
of pro-urokinase).
63. While an impure preparation may be defined in terms of the process used to make
it, the factor within the preparation responsible for the observed biological activity is unknown and unpatentable, per se. See Merck & Co. v. Olin Mathieson Chem. Corp., 253 F.2d
156 (4th Cir. 1958); see also In re Merz, 97 F.2d 599 (C.C.P.A. 1938); Kuehmsted v.
Farbenfabriken of Elberfeld Co., 179 F. 701 (7th Cir. 1910).
64. See Genentech, Inc. v. Bowen, 676 F. Supp. 301 (D.D.C. 1987); see also Herbert
A. Perkins et al., Risk of AIDS for Recipients of Blood Components from Donors Who Subsequently Developed AIDS, 70 J. HEMATOLOGY 1604 (1987) (discussing risks associated with
the receipt of AIDS-infected blood through transfusions and results of such transfusions as of
1987).
65. See Merck & Co., 253 F.2d 156; Sterling Drug Inc. v. Watson, 135 F. Supp. 173
(D.D.C. 1955) (holding that a patent application that disclosed sufficient "unexpected and
unobvious beneficial properties" not possessed by similar compounds or prior art to show
patentability may be approved even though the compound could be found in its natural form
in the human body); Smith, Kline & French Lab. v. Clark & Clark, 62 F. Supp. 971 (D.N.J.
1945), modified, 157 F.2d 725 (3d Cir. 1946); Parke-Davis & Co. v. H.K. Mulford Co., 189
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ering the patentability of aspirin, the Court of Appeals for the Seventh Circuit held:
[I]t makes no difference, so far as patentability is concerned, that
the medicine thus produced is lifted out of a mass that contained,
chemically, the compound; for, though the difference between [the
two] be one of purification only--strictly marking the line, however, where the one is therapeutically available and the others were
therapeutically unavailable-patentability would follow.6
Judge Learned Hand set forth essentially the same principle in a case
concerning the patentability of purified adrenalin:
But, even if [adrenalin] were merely an extracted product without
change, there is no rule that such products are not patentable.
Takamine was the first to make it available for any use by removing it from the other gland-tissue in which it was found, and, while
it is of course possible logically to call this a purification of the
principle, it became for every practical purpose a new thing commercially and therapeutically. That was a good ground for a patent. 67

Finally, determining inventorship based on priority in defining
the amino acid sequence of a biotherapeutic provides a simple,
straightforward test. Much of the patent litigation associated with
biological compounds stems from the fact that the criteria presently
being used by courts is not at all clear.
D. Tissue Plasminogen Activator Patents: The Problem of
Functional Definitions
Many of the problems created 'by defining biological inventions
in terms of function rather than structure are exemplified by the patents on tPA owned by Genentech. 61 Patent No. 4,752,603 (hereinafter "603") is based upon experiments in which tPA was purified from
the conditioned medium of Bowes melanoma cells, and it defines tPA
solely on the basis of its functional attributes. 69 Specifically, the inF, 95 (C.C.S.D.N.Y. 1911), rev'd on other grounds, 196 F. 496 (C.C.A.N.Y. 1912) (holding

that a substance extracted from animal tissue for medicinal use, which is practically and therapeutically new, may be patentable even though it differs from earlier preparations only in its
degree of purity).
66. Kuehmsted, 179 F. at 705.
67. Parke-Davis, 189 F. at 103.
68. See R. Stephen Crespi, Claims on Tissue Plasminogen Activator, 337 NATURE 317
(1989) (summarizing the claims made in these patents).
69. See Dingemen C. Rijken & Dlsir6 Collen, Purification and Characterizationof the
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ventors claim a "[h]uman plasminogen activator, having thrombolytic
properties, immunologically distinct from urokinase and having a specific activity of about 500,000 IU/mg. using the WHO First International Reference Preparation of tPA as [reference standard] ...."
It is difficult to see what criteria would justify the broad protection
afforded by these claims. The existence of a human plasminogen
activator distinct from urokinase was known long before the work
described in the patent7 and the specific activity72 cited appears to
have been incorrect by a wide margin. 73
Patent No. 4,766,075 (hereinafter "075") claims the sequence for
the human tPA gene.74 In contrast to the claims set forth in the 603
patent, this serves to distinguish clearly the protein being claimed
from the prior art, represents a definite scientific advance, and is
clearly deserving of patent protection. Unfortunately, the 075 patent
does not confine itself to structural definitions. The patent, in effect,
precludes competitors from using any recombinant techniques for
expressing or modifying the tPA gene. 75 Again, it is difficult to understand the criteria that would justify the granting of such protection.
The methods that'were used by the inventors in cloning and expressing tPA were not novel, 76 and it is unusual to award process patents
for old methodology simply because it is being applied to a new problem. 7

Plasminogen Activator Secreted by Human Melanoma Cells in Culture, 256 L BIOLOGICAL
CHEMISTRY 7035 (1981).
70. United States Patent No. 4,752,603, col. 10, 11.
36-44 (June 21, 1988).
71. See Genentech, Inc. v. Wellcome Found., 14 U.S.P.Q. 2d (BNA) 1363, 1365 (D.
Del. 1990); see also Crespi, supra note 68, at 317.
72. "Specific activity" is expressed as the amount of enzymatic activity that a particular
preparation has per amount of protein. As protein preparations become increasingly pure, their
specific activities should increase. ALBERT L. LEININGER, BIOCHEMISTRY 208-09 (2d ed.
1975). The abbreviation "1U/mg." is defined in the 603 patent as standing for international
units per milligram.
73. See Genentech, Inc., 14 U.S.P.Q. 2d at 1369.
74. United States Patent No. 4,766,075, col. 30, 11.
66-68 (Aug. 23, 1988).
75. Id.at col. 5, 11.21-34. The patent states:
The potential exists, in the use of recombinant DNA technology, for the preparation of various human tissue plasminogen activator derivatives, variously modified
by resultant single or multiple amino acid substitutions, deletions, additions or
replacements, for example, by means of site directed mutagenesis of the underlying
DNA . . . .All such allelic variations and modifications resulting in derivatives of
human tissue plasminogen activator are included within the scope of this invention ....

Id.
76. See Crespi, supra note 68, at 318.
77. See Amgen, Inc. v. United States Int'l Trade Comm'n, 902 F.2d 1532, 1534 (Fed.
Cir. 1990) (examiner of the Patent and Trademark Office rejecting claims to the process of
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A policy of limiting patent claims to the specific structure identified by an inventor would avoid the kind of overinclusiye functional
descriptions encountered in the Genentech patents. It is important to
recognize, however, that, even though a researcher who had isolated a
protein with a unique amino acid sequence would be entitled to be
the inventor of that molecule, this does not necessarily mean that he
would be awarded a patent.7" He must show that the protein he has
obtained does not infringe upon similar proteins discovered by others.79 It is in this regard, and not with regard to inventorship, that
the functional properties of a molecule are of major importance.
V.

FUNCTIONAL CHARACTERISTICS OF BIOTHERAPEUTICS
AND PATENT INFRINGEMENT

A.

FunctionalProperties as a Test for Infringement

While the structure of biological inventions is of prime importance in questions of inventorship, the therapeutic properties of these
molecules are of prime importance in questions of infringement. If all
that was necessary to avoid a claim of infringement was to show that
the challenged protein differed structurally from the patented protein,
patents on biotherapeutics would be of little or no value. They could
be avoided by simply introducing a trivial change in the amino acid
sequence of the protein or by isolating a naturally occurring variant.80
A balance between the overly broad protection of patents based
on function and the overly narrow protection of patents based strictly
on structure can be achieved by adopting the following policy: al-

producing recombinant erythropoietin partly "because he considered the claims to be to the
application of an old process to new starting materials and thus not patentable .... "); In re
Durden, 763 F.2d 1406, 1410 (Fed. Cir. 1985) (holding that "an otherwise old process becomes a new process when a previously unknown starting material, for example, is used in it
which is then subjected to a conventional manipulation or reaction .
78. See supra note 10 and accompanying text.
79. Under 35 U.S.C. section 271, a party who makes, uses, or sells a patented invention

is guilty of infringement.
80. Changes in amino acid sequence may be introduced by altering the DNA coding for
the protein using a technique termed site-directed mutagenesis. For a further discussion of
site-directed mutagenesis, see T.L. Blundell et al., Protein Engineering and Design, B324
PHIL. TRANSACTIONS ROYAL SOC'Y LONDON 447 (1989); Manfred Mutter, Nature's Rules and
Chemist's Tools: A Way for Creating Novel Proteins, 13 TRENDs BIOCHEMICAL SC. 260
(1988); Robin J. Leatherbarrow & Alan R. Fersht, Review: Protein Engineering, I PROTEIN
ENGINEERING 7 (1986); R. Wetzel, What is Protein Engineering?, I PROTEIN ENGINEERING 3
(1986).
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though a structurally altered form of a biotherapeutic is novel within
the meaning of section 102 of the Patent Act, it is not sufficiently
new to escape a charge of infringement unless the structural differences are nontrivial with respect to the therapeutic properties of the
molecule.
Such a position is consistent with past judicial policy. In Ziegler
v. Phillips Petroleum Co.,81 the court stated that, "[i]n recognition of
the fact that a patent would be virtually worthless if it did not protect
against devices which incorporate unimportant variations of the patented device, courts [have] developed the doctrine of equivalents .
,,.2 Under this doctrine, two inventions that do the same
work in substantially the same way to achieve substantially the same
result are the same.8 3 It is important to note that this is a functional
test, based on what the invention does. As such, it can lead to problems when applied to biological inventions that have also been defined in functional terms." This can best be seen using a concrete
example and, once again, tPA provides an illustration of the kind of
problem that can arise.
B.

Patents on tPA: Problems in Applying the Doctrine of
Equivalents to Inventions Defined by Their Functions

One of the main difficulties associated with the use of tPA as a
therapeutic is that it is rapidly cleared from the plasma (half-life =
three to six minutes).,5 As a result, large quantities of the drug must
be continually infused in order to attain therapeutically effective blood
concentrations.8 6 Burroughs Wellcome modified the structure of tPA
in such a way that the8 plasma
half-life of the molecule was increased
7
to about sixty minutes.
All other things being equal, it is difficult to imagine a change
with greater therapeutic implications. The amount of damage caused

81. 483 F.2d 858 (5th Cir. 1973).
82. Ideat 868.
83. See Graver Tank & Mfg. v. Linde Air Prods., 339 U.S. 605, 608-09 (1950).
84. For a discussion of the problems created by functional definitions with regard to
inventorship, see supra notes 68-79 and accompanying text. The present section deals with
the problem of functional definitions with regard to infringement.
85. See Loscalzo & Braunwald, supra note 13.
86. See Marsha F. Goldsmith, Pro-UK: Another Entry in the Thrombolytic Arena, 253
JAMA 1694 (1985).
87. See Genentech, Inc. v. Wellcome Found., 14 U.S.P.Q. 2d (BNA) 1363, 1369 (D.
Del. 1990).
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by a heart attack is directly related to the length of time that the
heart is deprived of oxygen due to an occluded blood vessel.8" Since
tPA must be infused, a heart attack victim cannot ordinarily receive
treatment before arriving at a hospital. Increasing the half-life of the
molecule opens up the possibility of administering tPA as a single
bolus injection. Thus, it might be possible for an individual at high
risk of suffering a heart attack to carry tPA for self-administration.
Also, since substantially less tPA would be required to achieve the
same plasma concentration, it should be possible to reduce the cost of
treatment (presently about $2,000).89
In spite of these advantages, a jury in the District Court for the
District of Delaware found that Wellcome's version of tPA infringed
upon Genentech's patents.' This decision appears to be a clear misapplication of the doctrine of equivalents and to be inconsistent with
the patent statute's objective of promoting innovation.
The jury's decision becomes more understandable, however,
when one considers Wellcome's invention in light of Genentech's
patent claims. As stated previously, these encompass all human plasminogen activators, immunologically distinct from tPA and with a
specific activity of about 500,000 IU/mg. 9' Wellcome's version of
the tPA molecule had all of these characteristics. Since the claims
made on inventions that have been awarded patents by the Patent and
Trademark Office are given a presumption of validity,' a jury might
be persuaded that infringement had occurred regardless of the potential therapeutic advantages of Wellcome's form of the molecule. In
this regard, it is worth noting that, overall, the similarities in the tPAs

88. See M. Verstraete, Even if the Efficacy of Intracoronary Thrombolysis is Proven,
This Approach Is a Death Issue in Terms of Public Health, in 7 PROGRESS IN FIBRINOLYSIS,

supra note 62, at 25-29 (stating that the timely reopening of an acutely occluded coronary
artery actually saves more myocardial tissue; therefore, improving myocardial function, reducing the reinfarction rate, and decreasing early and late mortality are reasonable assumptions);
W.H. Bleifeld et al., The Clinical Relevance of Opening a Coronary Artery in Patients with
Acute Myocardial Infarction, in 7 PROGRESS IN FIBRINOLYSIS, supra note 62, at 30-38

(discussing the analysis of the underlying mechanisms leading to an acute myocardial infarction, methods used for reperfusion, results of thrombolytic treatment, especially with regard to'
rate of reopening ventricular function and post-thrombolytic treatment).
89. Marcia Barinaga, Genentech's Boom is Boosted by New Clinical Trial Data, 332
NATURE 387 (1988).
90. Patents: T-PA Variants are Equivalent to Genentech's Patented T-PA, 39 PAT.
TRADIEMARK & COPYRIGHT J. (BNA) 503 (1990).

91. See supra notes 70-73 and accompanying text.
92. Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1375 (Fed. Cir.
1986).
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far outweigh their differences: both lead to the reperfusion of occluded blood vessels by promoting the dissolution of fibrin clots; both
work by converting plasminogen to plasmin; and the vast majority of
the amino acids in the molecules are identical. Using the most typical
phrasing of the doctrine of equivalents test,93 it might be concluded
that the molecules performed substantially the same work, in substantially the same way, to achieve substantially the same result.9
The jury was, therefore, presented with a molecule that was
clearly different from Genentech's both structurally and in terms of a
therapeutically significant property, but that nevertheless fell within
the literal scope of Genentech's claims. This conflict is the direct
result of the Patent Office permitting per se patents on biotherapeutics
such as tPA to be based strictly on a functional description of the
molecule. Since an inventor cannot describe all of the properties that
may have a significant impact on therapeutic potential, patents based
on biological functions give patent holders an undeservedly broad
range of equivalents. As a consequence, new inventions that offer
substantial advantages over patented molecules may nevertheless be
found to infringe.
Requiring that patents describe biological inventions in terms of
structure would avoid these problems and would greatly simplify
disputes over infringement. One of the main advantages of such a
requirement would be that it would allow the scope of patent claims
to be determined by the molecules themselves. Side by side comparisons could be made between the patented and the allegedly infringing
molecules with respect to any function, even those whose therapeutic
significance was not appreciated at the time the patent application was
filed.
VII.

CONCLUSION

Patents are limited monopolies granted for the purpose of promoting innovation. To succeed, they must strike a balance between
protecting inventions and preserving competition. If patent claims are
permitted to exceed the scope of an inventor's contribution, then
competition is unfairly eliminated and innovation is repressed. As the

93. See
ing that, "if
substantially
shape.").
94. See

Graver Tank & Mfg. v. Linde Air Prods., 339 U.S. 605, 608-09 (1950) (providtwo devices do the same work in substantially the same way, and accomplish
the same result, they are the same, even though they differ in name, form, or
supra notes 83, 93 and accompanying text.
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patent dispute between Burroughs Wellcome and Genentech demonstrates, this is exactly the effect of allowing biotherapeutics to be
defined based upon their functional properties. Since a molecule has
an unlimited number of potentially important functions, patents in
which inventions are defined in this way must necessarily be ambiguous. Questions of novelty and infringement may become confused and
difficult to resolve.
A policy that requires biological inventions to be defined in
structural terms would avoid the patent problems created by the inherent ambiguities of functional definitions. Under such a policy, a
biotherapeutic with a structure that had not been previously described
would be novel and the party who determined that structure would be
entitled to inventorship. Competition among inventors would be preserved by limiting patent claims to the exact structure described and
by using the functional characteristics of proteins to settle questions
of infringement. For example, if A patented a protein and later, B
claimed a protein that differed in only three amino acids, then the
question of whether B's invention infringed upon A's would depend
upon whether those particular amino acids were important for some
significant function. Thus, inventors would be encouraged to look for
natural variants with better therapeutic properties and to attempt to
improve the therapeutic properties of proteins through techniques such
as site-directed mutagenesis.
Finally, regardless of the policy adopted, patent disputes over
biological molecules will be simplified by keeping clearly in mind the
exact provisions of the patent statute that are at issue. The commingling of distinct statutory sections and the misleading characterization
of biological inventions as "products of nature" has created considerable confusion. These practices serve only to obscure issues and to
make court battles over the patent rights to biological inventions more
probable and less predictable.
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